Related Experiment Video
Updated: Sep 10, 2025

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
Published on: April 12, 2019
Dynorphin A Impairs Mitochondrial Biogenesis in Osteosarcoma Cells by Increasing SP-1
Yaxiong Dai1, Jian Zhang2, Yingzhen Peng3
1Department of Orthopedics, Huanggang Central Hospital of Yangtze University, Huanggang, China.
None:
Mitochondria are vital for energy generation, apoptosis control, and cellular metabolism. As a result, they represent an attractive therapeutic target in cancer treatment, particularly osteosarcoma (OS). Despite evidence indicating that Dynorphin A exhibits anti-tumor characteristics via multiple mechanisms, its influence on the physiology of osteosarcoma (OS) has not been thoroughly investigated. In this study, we explore the impacts of Dynorphin A on mitochondrial function and biogenesis within human OS U2OS cells. Human osteosarcoma (U2OS) cells were treated with Dynorphin A at varying concentrations for 48 h. Cell viability and cytotoxicity were assessed using the Cell Counting Kit-8 (CCK-8) and LDH assay, respectively. Mitochondrial function was evaluated by measuring complex IV activity, oxygen consumption rate (OCR), and ATP production, while mitochondrial biogenesis was analyzed by determining the mtDNA/nDNA ratio, mitochondrial protein expression (NDUFB8 and MTCO2), and mitochondrial mass (MitoTracker Red staining). The expression of key mitochondrial regulators (PGC-1α, Nrf1, TFAM) and SP-1 was quantified using real-time RT-PCR and Western blot analysis. Our findings reveal that Dynorphin A notably decreases cell viability and enhances the release of lactate dehydrogenase (LDH)., indicating cytotoxicity. It also impaired mitochondrial function, as evidenced by a decrease in complex IV activity, oxygen consumption, and ATP production. Additionally, Dynorphin A suppressed mitochondrial biogenesis, shown by a reduced mtDNA/nDNA ratio, lower expression of mitochondrial proteins (NDUFB8 and MTCO2), and decreased mitochondrial mass. Furthermore, Dynorphin A downregulated key mitochondrial regulators, including PGC-1α, Nrf1, and TFAM. Notably, Dynorphin A also upregulated SP-1 expression, and silencing SP-1 reversed its effects on mitochondrial function and biogenesis. These findings suggest that Dynorphin A exerts antitumor effects by disrupting mitochondrial function and biogenesis in OS cells.
More Related Videos
06:00Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines
Published on: September 13, 2017
07:31A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
Published on: May 3, 2021
Related Concept Videos
Formation of Muscle Fibers from Myoblasts
Muscle progenitor cells (MPCs) are formed from the myotomes. MPCs express genes that encode the transcription factors Pax3 and Pax7. Along with Pax 3/7, other transcription...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
The Nucleolus
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
Abnormal Proliferation
Destabilization of Microtubules